Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie Inc. has lowered its adjusted EPS guidance range for Q2 and FY23 due to certain IPR&D and milestone expenses, disappointing investors further. ABBV has fallen significantly to levels last seen in early 2022, suggesting investors likely reflected substantial headwinds relating to Humira's patent expiration. AbbVie could face near-term growth challenges as it navigates the competitive landscape facing its highly successful earnings driver.

AbbVie: Humira Overhang Is A Fantastic Buying Opportunity

CareTrust REIT

Viatris

If you worry you won't have enough saved up by retirement, dividend stocks can help boost your income. Allocating part of your retirement savings to such equities can reduce depletion of your savings.

Why Dividend Stocks Should Be a Key Part of Your Retirement Plan

AbbVie underperformed the S&P 500 in the last few months - similar to the entire pharmaceutical sector. In the case of ABBV, the Humira patent cliff and the introduction of new biosimilars by different competitors might be a reason for the declining stock. The company remains undervalued, in my opinion, and even lower Humira sales are more than reflected by the stock price.

AbbVie: A Buy Despite Declining Humira Sales

Duke Energy

Alphabet

Robert Half Int.

Republic Services

Welltower

Investing features many similarities to the game of baseball, which helps drive the case for the best long-term stocks in July. Unlike the NFL where teams play only 17 regular-season games, in MLB, there are 876 – no, excuse me, 162 games.

The 7 Best Long-Term Stocks to Buy in July

AbbVie is a top-shelf dividend stock. However, the company's free cash flows are set to decline this year in response to biosimilar competition.

Is AbbVie's Dividend Yield Safe?

Verizon

AbbVie is a heavily discounted healthcare stock whose business is in fine shape. Verizon offers a mouthwatering dividend at a very manageable payout ratio.

Got $5,000? These Are 3 of the Best Stocks to Buy in July

NORTH CHICAGO, Ill. , July 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2023 financial results on Thursday, July 27, 2023, before the market opens.

AbbVie to Host Second-Quarter 2023 Earnings Conference Call

AbbVie stock has been upgraded to a buy again due to its attractive yield and less demanding valuation, despite expectations of a down year in 2023. The healthcare company is seen as a resilient investment choice in uncertain economic times, offering a 4.4% dividend yield and a low beta of 0.54. Despite a decline in sales of its biggest drug, Humira, AbbVie's portfolio of growing drugs and promising pipeline suggest potential for long-term growth.

AbbVie: Use This Buying Opportunity (Rating Upgrade)

ASML Hld

Chevron

Honeywell

Microsoft

NextEra Energy

NuScale Power Corp

With the latest encouraging read on inflation sending the market on a high to end the first half of this year, the idea of acquiring the best forever stocks may seem overly cautious. After all, with sentiment strong on apparently justifiable reasons, investors may be better served with risk-on securities.

The 7 Best Forever Stocks to Buy for July 2023

AbbVie is about to face stiffer competition for its blockbuster rheumatoid arthritis drug Humira from a new biosimilar about to be launched in the US. Celltrion Healthcare, a South Korean company, has introduced Yuflyma, a biosimilar version Humira, in the United States.

AbbVie braces for increased Humira competition from cheaper biosimilar

Bristol-Myers

Johnson & Johnson

AbbVie is a Dividend King with a high yield. Bristol Myers Squibb is an underrated bargain.

3 Spectacular Dividend Stocks to Buy in July

India's Biocon Biologics said on Monday it has launched a biosimilar version of AbbVie's blockbuster rheumatoid arthritis drug Humira in the United States.

India's Biocon Biologics launches biosimilar for AbbVie's Humira in US

Merck

Each has a blockbuster therapy that is likely facing declining sales. But both companies' pipelines have more than 100 programs.

Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys

Coherus BioSciences

Coherus BioSciences said on Monday it has launched a copycat version of AbbVie's Humira in the United States at a discount of over 85% to the blockbuster arthritis drug.

Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira

Brookfield Renewable Partners

Enterprise Products Partners

AbbVie is a Dividend King that's poised to deliver robust long-term growth. Brookfield Renewable should benefit tremendously from the increased demand for clean energy.

3 Magnificent Dividend Stocks to Buy Hand Over Fist in July

Genmab - ADR

In clinical trials, epcoritamab proved highly effective in treating a certain kind of lymphoma. The cancer drug, developed jointly by AbbVie and Genmab, has a huge potential market.

Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

Organon & Co

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while another drugmaker entered the market with a much more modest discount to the branded medicine's list price.

Organon, Samsung Bioepis launch copycat for athritis drug Humira at 85% discount

Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January.

Sandoz launches rival version of AbbVie's arthritis drug Humira

AbbVie's ABBV, +1.53% rheumatoid arthritis drug Humira, one of the top-selling biopharmaceutical products of all time, will have new lower-cost competition starting Saturday. But even as nearly identical competitors become available at big discounts to Humira's list price, they may be hard-pressed to knock the blockbuster drug off its perch, analysts say.

For AbbVie's blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts say

Eli Lilly

Pharmaceutical stocks have not shared in this year's bull rally. Year to date, the S&P Pharmaceuticals Select Industry index is down 1% while the benchmark S&P 500 index has gained 15%.

The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023

Kimberly-Clark

Northwest Natural Gas

If you are focused on investing for income look no further. Dividend Kings are stocks that have raised their dividends for at least 50 consecutive years, a feat made possible by uber-consistent business management and commitment to shareholders.

3 Dividend Kings Yielding Royal Sums

AbbVie Inc. ABBV, +0.54% said late Thursday its vice chairman and president will take on the added role of chief operating officer, according to a filing with the Securities and Exchange Commission. The drug maker said it appointed Robert Michael as president and COO.

AbbVie president given added COO duties

ABM Industries

Archer-Daniels-Midland Company

Black Hills

Cincinnati Financial

California Water Service Group

Federal Realty Investment Trust

Gorman-Rupp

Leggett & Platt

Altria

National Fuel Gas

Target

Universal Corp

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 50 Dividend Kings screened as of June 27, 2023, represented nine of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 20.35%-40.04% topped-by ABM Industries, and Gorman-Rupp. By yield, MO tops-all. Top-ten Kingly July yields from NFG, BKH, ABBV, NWN, FRT, CDUAF, MMM, UVV, LEG, & MO averaged 5.4%.

July Dividend Kings: 5 Buys, 4 To Watch

Amgen

Pfizer

Some of the biggest names in healthcare are on sale right now. J&J, AbbVie, Bristol Myers, Amgen, and Pfizer all trade at low valuations.

5 High-Yielding Dividend Stocks That Are Bargain Buys

AbbVie may be an active player on the merger and acquisition scene in 2023. Blueprint Medicines and Krystal Biotech are two budget-friendly targets.

News for AbbVie Stock (ABBV)